Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs

被引：8
|
作者：
Simoens S. [1 ]
Cassiman D. [2 ]
Picavet E. [1 ]
Dooms M. [3 ]
机构：
[1] Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, 3000 Leuven, Onderwijs en Navorsing 2
[2] Department of Hepatology, University Hospital Leuven, Leuven
[3] Hospital Pharmacy, University Hospital Leuven, Leuven
来源：
Drugs & Therapy Perspectives | 2011年 / 27卷 / 10期
关键词：
Orphan Drug; Healthcare Payer; Orphan Designation; Belgian Hospital; Hospital Price;
D O I：
10.2165/11601640-000000000-00000
中图分类号：
学科分类号：
摘要：
Hospital purchase prices substantially exceed compounding production costs in Belgium for selected orphan drugs that had low costs of research and development and market access procedures. As a result, healthcare payers seem to be paying too much for these orphan drugs and there are arguments for price reductions. Pharmacies can consider compounding, rather than purchasing, these orphan drugs. © 2011 Adis Data Information BV. All rights reserved.
引用
收藏
页码：24 / 26
页数：2
相关论文
共 50 条
  • [31] Rare diseases and orphan drugs: 500 years ago
    Dooms, Marc M.
    ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [32] Rare diseases and orphan drugs: 500 years ago
    Marc M. Dooms
    Orphanet Journal of Rare Diseases, 10
  • [33] The availability and affordability of orphan drugs for rare diseases in China
    Gong, Shiwei
    Wang, Yingxiao
    Pan, Xiaoyun
    Zhang, Liang
    Huang, Rui
    Chen, Xin
    Hu, Juanjuan
    Xu, Yi
    Jin, Si
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [34] Orphan Drugs for Rare Diseases: Grounds for Special Status
    Picavet, Eline
    Dooms, Marc
    Cassiman, David
    Simoens, Steven
    DRUG DEVELOPMENT RESEARCH, 2012, 73 (03) : 115 - 119
  • [35] Rare diseases and orphan drugs in Eastern European Countries
    Stefanov, Rumen
    Taruscio, Domenica
    EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2009, 6 (04): : 289 - 293
  • [36] Rare diseases, orphan drugs and their regulation: questions and misconceptions
    Erik Tambuyzer
    Nature Reviews Drug Discovery, 2010, 9 : 921 - 929
  • [37] Drugs for Rare Diseases: Influence of Orphan Designation Status on Price
    Picavet, Eline
    Dooms, Marc
    Cassiman, David
    Simoens, Steven
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2011, 9 (04) : 275 - 279
  • [38] Current progress in the management of rare diseases and orphan drugs in China
    Gong, Shiwei
    Jin, Si
    INTRACTABLE & RARE DISEASES RESEARCH, 2012, 1 (02) : 45 - 52
  • [39] Orphan drugs. New opportunities for the treatment of rare diseases
    Beck, M.
    INTERNIST, 2016, 57 (11): : 1132 - 1137
  • [40] Therapeutic potential of orphan drugs for the rare skeletal muscle diseases
    Swiderski, Kristy
    Lynch, Gordon S.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (12): : 1397 - 1426
12345